Nov 4 (Reuters) - The U.S. Food and Drug Administration has approved Journey Medical's drug for the treatment of a long-term skin condition called rosacea, the company said on Monday.
(Reporting by Sruthi Narasimha Chari, Puyaan Singh and Mariam Sunny in Bengaluru; editing by Alan Barona and Shilpi Majumdar)
((mailto:SruthiNarasimha.Chari@thomsonreuters.com; mailto:puyaan.singh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.